Viatris Inc
No SEC Form 4 filings for $VTRS in the last 30 days.
Viatris (VTRS) reported Q2 adjusted EPS of $0.69 on revenue of about $3.8b, with full-year guidance raised for revenue, adjusted EBITDA, and adjusted EPS, according to the company. Despite the guidance increase, net loss widened to $118.8m and basic EPS loss widened. The stock was up less than 1% near $16.
Viatris reported Q2 2026 results on Aug. 6, with total revenue of $3.76B, up 5% YoY, and adjusted EBITDA of $1.2B, up 8% operationally. It posted a U.S. GAAP net loss of $119M. The company cited strong Greater China performance, U.S. FDA approval of Gwyn Lo, Tyrvaya rights sale, raised 2026 guidance midpoints, returned about $550M to shareholders, and cut gross leverage to 2.9x.
Viatris (VTRS) shares fell about 7.7% as investors weighed execution and supply-disruption risks despite improved outlook. The company reported Q2 2026 revenue of about $3.8B (+5%) and adjusted EPS of $0.69, and raised 2026 guidance. It warned second-half revenue could be reduced by $100M to $150M due to Nashik remediation and FDA Form 483 issues, plus a GAAP net loss of about $119M tied largely to a planned Tyrvaya rights sale.
Over the past 7 days, alphai's AI scored 17 news stories mentioning VTRS (Viatris Inc). Coverage has skewed bullish: 9 bullish, 5 neutral, and 3 bearish.
Recent VTRS coverage spans earnings, market movers and financial news.
Guidance lift is offset by wider losses and operational setbacks, keeping the stock range-bound as investors weigh pipeline upside vs near-term profit risk.
Guidance lift plus FDA approval and Tyrvaya divestiture are likely to improve forward earnings visibility and reduce balance-sheet risk.
Guidance raise is being offset by quantified second-half revenue risk tied to Nashik remediation and FDA Form 483 observations, driving near-term downside sentiment.
Raised 2026 guidance and cash generation support a bullish fundamental read-through, but the stock fell on second-half supply and margin headwinds.
Beat on earnings and revenues plus a guidance raise, driven largely by Greater China strength, should support near-term estimates and sentiment.
alphai scores every news story that mentions VTRS with an AI model for sentiment and relevance, and aggregates insider trades from Viatris Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Viatris (VTRS) reported Q2 adjusted EPS of $0.69 on revenue of about $3.8b, with full-year guidance raised for revenue, adjusted EBITDA, and adjusted EPS, according to the company. Despite the guidance increase, net loss widened to $118.8m and basic EPS loss widened. The stock was up less than 1% near $16.
4 min readViatris reported Q2 2026 results on Aug. 6, with total revenue of $3.76B, up 5% YoY, and adjusted EBITDA of $1.2B, up 8% operationally. It posted a U.S. GAAP net loss of $119M. The company cited strong Greater China performance, U.S. FDA approval of Gwyn Lo, Tyrvaya rights sale, raised 2026 guidance midpoints, returned about $550M to shareholders, and cut gross leverage to 2.9x.
6 min readViatris (VTRS) shares fell about 7.7% as investors weighed execution and supply-disruption risks despite improved outlook. The company reported Q2 2026 revenue of about $3.8B (+5%) and adjusted EPS of $0.69, and raised 2026 guidance. It warned second-half revenue could be reduced by $100M to $150M due to Nashik remediation and FDA Form 483 issues, plus a GAAP net loss of about $119M tied largely to a planned Tyrvaya rights sale.
6 min readViatris (NASDAQ:VTRS) reported Q2 2026 adjusted EPS of $0.69 on revenues of $3.8 billion, topping analyst estimates of $0.61 and $3.67 billion, and raised full-year guidance. Updated 2026 outlook calls for revenues of $14.55B to $14.95B, adjusted EBITDA $4.30B to $4.50B, and adjusted EPS $2.45 to $2.59. Shares fell 3.29% to $17.07.
6 min readViatris (VTRS) reported Q2 2026 adjusted EPS of 69 cents, above the Zacks consensus of 62 cents. Revenues rose 5% to $3.76 billion, exceeding the $3.68 billion estimate, driven by Developed Markets and a 21% jump in Greater China to $713.8 million. Viatris raised 2026 revenue guidance to $14.55-$14.95 billion and adjusted EPS to $2.45-$2.59.
6 min readViatris (VTRS) reported Q2 2026 revenue of $3.8B, up 3.5% operationally, driven by a 16% Greater China surge and U.S. demand for complex generics and hormone patches. Management raised full-year guidance despite a $100–150M expected impact from Nashik plant supply disruptions. Viatris also cited FDA approvals and pipeline progress.
6 min readFMR LLC filed a Schedule 13G reporting beneficial ownership of 96,362,102.65 shares of Viatris Inc. common stock, representing 8.3% of the outstanding class as of the reporting date. The filing attributes sole voting power of 87,847,830.22 shares and sole dispositive power of 96,362,102.65 shares, with Abigail P. Johnson also listed as a beneficial owner.
2 min readViatris (VTRS) reported Q2 results. Total net sales were $3.75 billion versus a $3.65 billion two-analyst average, up 5% year over year. Developed Markets net sales were $2.19 billion, slightly above estimates, while Greater China was $713.8 million, above estimates and up 21.2% year over year.
2 min readViatris Inc. reported Q2 2026 sales of $3,745.9 million versus $3,569.0 million a year earlier, with revenue of $3,756.8 million versus $3,582.1 million. Net loss was $118.8 million versus $4.6 million. For six months, sales rose to $7,255.6 million and net income was $57.6 million versus a $3,046.6 million loss a year ago.
3 min readViatris Inc. (VTRS) reported a wider Q2 net loss of $118.8 million versus a $4.6 million loss a year earlier. GAAP diluted loss per share was $0.10. The company also raised its 2026 guidance, citing ongoing business performance and new product sales, according to the company.
4 min read
